Aliases & Classifications for Drug Dependence

MalaCards integrated aliases for Drug Dependence:

Name: Drug Dependence 12 55 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:9974
ICD9CM 35 304.6 304.60

Summaries for Drug Dependence

Disease Ontology : 12 A substance dependence that involves the continued use of drugs despite problems related to use of the substance.

MalaCards based summary : Drug Dependence is related to polysubstance abuse and hallucinogen dependence. An important gene associated with Drug Dependence is OPRM1 (Opioid Receptor Mu 1), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Nicotine and Cocaine have been mentioned in the context of this disorder. Affiliated tissues include brain, breast and myeloid, and related phenotypes are behavior/neurological and homeostasis/metabolism

Related Diseases for Drug Dependence

Diseases related to Drug Dependence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 100)
# Related Disease Score Top Affiliating Genes
1 polysubstance abuse 32.0 CNR1 DRD2 DRD3
2 hallucinogen dependence 31.2 CNR1 PENK
3 chronic pain 30.4 CNR1 OPRM1
4 neonatal abstinence syndrome 30.3 OPRD1 OPRK1 OPRM1
5 opioid abuse 30.2 DRD2 OPRM1 PDYN
6 depression 30.1 BDNF CRH SLC6A4
7 social phobia 30.0 DRD2 SLC6A4
8 antisocial personality disorder 30.0 ANKK1 DRD2 SLC6A4
9 opiate dependence 29.6 DRD2 DRD3 OPRD1 OPRK1 OPRM1 PDYN
10 personality disorder 29.5 BDNF DRD2 DRD3 SLC6A4
11 cocaine dependence 29.2 CHRNB3 DRD2 DRD3 OPRD1 OPRK1 OPRM1
12 substance dependence 28.9 BDNF CNR1 DRD2 DRD3 OPRD1 OPRK1
13 obsessive-compulsive disorder 28.9 BDNF DRD2 DRD3 SLC6A4
14 anorexia nervosa 28.8 BDNF CRH POMC SLC6A4
15 withdrawal disorder 28.8 CNR1 CRH OPRM1 PDYN POMC
16 post-traumatic stress disorder 28.6 BDNF CNR1 CRH DRD2 SLC6A4
17 anxiety 28.4 BDNF CNR1 CRH OPRL1 SLC6A4
18 attention deficit-hyperactivity disorder 28.1 ANKK1 BDNF DRD2 DRD3 OPRM1 SLC6A4
19 tobacco addiction 27.8 ANKK1 CHRNA6 CHRNB3 DRD2 OPRM1
20 disease of mental health 26.6 BDNF CNR1 CRH DRD2 DRD3 OPRM1
21 alcohol dependence 23.5 ANKK1 BDNF CHRM2 CHRNA6 CNR1 DRD2
22 alcohol-induced mental disorder 10.8 DRD2 SLC6A4
23 atypical depressive disorder 10.7 CRH SLC6A4
24 malaria 10.7
25 cannabis dependence 10.7
26 barbiturate dependence 10.7
27 cyclic vomiting syndrome 10.6 CNR1 OPRM1
28 obsessive-compulsive personality disorder 10.6 DRD3 SLC6A4
29 morphine dependence 10.6 OPRD1 OPRK1 OPRM1
30 hypothalamic disease 10.6 CRH POMC
31 delusional disorder 10.6 DRD2 DRD3
32 alexithymia 10.6 ANKK1 DRD2 SLC6A4
33 pituitary carcinoma 10.6 CRH POMC
34 alcoholic psychosis 10.5 DRD2 SLC6A4
35 retrograde amnesia 10.5 PDYN POMC SLC6A4
36 uremic pruritus 10.5 CNR1 OPRK1
37 tardive dyskinesia 10.5 DRD2 DRD3
38 acth deficiency, isolated 10.5 CRH POMC
39 phobic disorder 10.5 OPRK1 SLC6A4
40 pathological gambling 10.5 DRD2 DRD3 SLC6A4
41 nelson syndrome 10.4 CRH POMC
42 impulse control disorder 10.4 ANKK1 DRD2 DRD3
43 opioid addiction 10.4 DRD2 OPRD1 OPRK1 OPRM1
44 migraine without aura 10.4 DRD2 DRD3 SLC6A4
45 sheehan syndrome 10.4 CRH POMC
46 hypoadrenalism 10.4 CRH POMC
47 chronic fatigue syndrome 10.3 CRH POMC SLC6A4
48 restless legs syndrome 10.2 DRD2 DRD3 POMC
49 generalized anxiety disorder 10.2 BDNF DRD2 SLC6A4
50 childhood disintegrative disease 10.2 BDNF POMC

Graphical network of the top 20 diseases related to Drug Dependence:



Diseases related to Drug Dependence

Symptoms & Phenotypes for Drug Dependence

MGI Mouse Phenotypes related to Drug Dependence:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.33 CHRNB3 DRD3 CNR1 OPRD1 CRH BDNF
2 homeostasis/metabolism MP:0005376 10.2 DRD3 CNR1 OPRD1 ACKR1 CRH BDNF
3 growth/size/body region MP:0005378 10.11 DRD3 CNR1 CRH BDNF DRD2 CHRM2
4 integument MP:0010771 10.07 CNR1 OPRD1 CRH BDNF DRD2 CHRM2
5 adipose tissue MP:0005375 10.02 DRD3 CNR1 CRH DRD2 OPRM1 PDYN
6 endocrine/exocrine gland MP:0005379 10.01 DRD2 CRH BDNF OPRM1 SLC6A4 OPRK1
7 nervous system MP:0003631 10 CHRNA6 DRD3 CNR1 OPRD1 CRH BDNF
8 digestive/alimentary MP:0005381 9.98 DRD3 CNR1 BDNF DRD2 OPRM1 PDYN
9 no phenotypic analysis MP:0003012 9.61 CNR1 OPRD1 CRH BDNF DRD2 PDYN
10 normal MP:0002873 9.23 CNR1 CRH BDNF DRD2 OPRM1 SLC6A4

Drugs & Therapeutics for Drug Dependence

Drugs for Drug Dependence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 409)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicotine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 54-11-5 942 89594
2
Cocaine Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-36-2 5760 446220
3
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52485-79-7 40400 644073
4
Heroin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 561-27-3 5462328
5
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 76-99-3 4095
6
Naloxone Approved, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 465-65-6 5284596
7
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 64-17-5 702
8
Methamphetamine Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 537-46-2 10836
9
Dextromethorphan Approved Phase 4,Phase 3 125-71-3 5360696 5362449
10
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 93-14-1 3516
11
Dasatinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 302962-49-8 3062316
12
Metformin Approved Phase 4,Phase 3,Phase 1,Phase 2 657-24-9 14219 4091
13
Famotidine Approved Phase 4 76824-35-6 3325
14
Abatacept Approved Phase 4,Phase 3,Phase 2,Phase 1 332348-12-6 10237
15
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 155213-67-5 392622
16
Losartan Approved Phase 4 114798-26-4 3961
17
Lamivudine Approved, Investigational Phase 4,Phase 2,Phase 1 134678-17-4 60825
18
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
19
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
20
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
21
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
22
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
23
Valproic Acid Approved, Investigational Phase 4,Not Applicable 99-66-1 3121
24
Aripiprazole Approved, Investigational Phase 4,Phase 3 129722-12-9 60795
25
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
26
Histamine Approved, Investigational Phase 4,Phase 2 75614-87-8, 51-45-6 774
27
Entecavir Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 142217-69-4 153941
28
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 16590-41-3 5360515
29
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 143491-57-0 60877
30
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
31
Oxytocin Approved, Vet_approved Phase 4,Phase 2,Not Applicable 50-56-6 439302 53477758
32
Thrombin Approved, Investigational Phase 4,Phase 3,Phase 1
33
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 3 142340-99-6 60871
34
Caffeine Approved, Nutraceutical Phase 4 58-08-2 2519
35
Creatine Approved, Investigational, Nutraceutical Phase 4 57-00-1 586
36
Adefovir Investigational Phase 4,Phase 3 106941-25-7
37 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Chlorpheniramine, phenylpropanolamine drug combination Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Narcotic Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Narcotics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
45 Analgesics, Opioid Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Nicotinic Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Opiate Alkaloids Phase 4,Phase 2,Phase 3,Not Applicable
48 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Excitatory Amino Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1
50 Excitatory Amino Acids Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 419)
# Name Status NCT ID Phase Drugs
1 Buprenorphine and Integrated HIV Care Evaluation Unknown status NCT00124358 Phase 4 Buprenorphine
2 Intensive Outpatient Versus Outpatient Treatment With Buprenorphine Among African Americans Completed NCT01096550 Phase 4
3 A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects (Study P04843)(COMPLETED) Completed NCT00605033 Phase 4 Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484;Subutex, Buprenorphine Hydrochloride, SCH 28444
4 HIV, Buprenorphine, and the Criminal Justice System (STRIDE2) Completed NCT03583138 Phase 4 buprenorphine
5 A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users (P05042)(COMPLETED) Completed NCT00604188 Phase 4 Suboxone (SCH 000484);Subutex (SCH 028444)
6 Treatment of Polydrug-Using Opiate Dependents During Withdrawal Completed NCT00367874 Phase 4 Buprenorphine;Valproate
7 Abilify Therapy for Reducing Comorbid Substance Abuse Completed NCT00208169 Phase 4 Aripiprazole
8 Dexmedetomidine Versus Placebo in Endoscopic Retrograde Cholangiopancreatography (ERCP) Sedation Completed NCT01070680 Phase 4 Precedex;sodium chlorid 0,9%
9 Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia Completed NCT02396979 Phase 4 Methadone
10 Association of Functional COMT Val108/Met Polymorphism With Smoking Cessation in Nicotine Replacement Therapy Completed NCT01980550 Phase 4 sublingual nicotine
11 Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Completed NCT00798538 Phase 4
12 Buprenorphine and Integrated HIV Care Completed NCT00317460 Phase 4
13 Dexmedetomidine for Sepsis in ICU Randomized Evaluation Trial Completed NCT01760967 Phase 4 Dexmedetomidine
14 Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients Completed NCT00879996 Phase 4 Methadone;Buprenorphine/naloxone
15 Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes Completed NCT01864174 Phase 4 Metformin XR;Metformin IR;Placebo matching with Metformin XR;Placebo matching with Metformin IR
16 Phase IV Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder Completed NCT01227668 Phase 4 Aripiprazole;Placebo
17 The Whole Day First Grade Program Completed NCT00257088 Phase 4
18 Immunogenicity and Safety Study of rThrombin in Surgical Hemostasis Completed NCT00813904 Phase 4
19 Safety Sudy of Atazanavir Boosted With Ritonavir in the Treatment of HIV Infection in Pediatric Patients Completed NCT01691794 Phase 4 Atazanavir;Ritonavir
20 Effects of Famotidine on the Pharmacokinetics of Atazanavir When Coadministered to Participants With HIV Infection Completed NCT01232127 Phase 4 Atazanavir;Atazanavir;Ritonavir;Ritonavir;Tenofovir (TDF);Tenofovir (TDF);Nucleoside Reverse Transcriptase Inhibitor (NRTI);Nucleoside Reverse Transcriptase Inhibitor (NRTI);Famotidine (FAM);Famotidine (FAM)
21 Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib Completed NCT01660906 Phase 4 Dasatinib
22 Suboptimal Responders to Adefovir Switching to Entecavir Completed NCT00718887 Phase 4 Entecavir;Adefovir/Entecavir
23 A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania Completed NCT00261443 Phase 4 Lithium or Valproate with placebo (PBO);Lithium or Valproate with Aripiprazole
24 A Study in Korea of Entecavir Versus Lamivudine in Adults With Chronic Hepatitis B Infection Completed NCT00393484 Phase 4 Entecavir;Lamivudine Placebo;Lamivudine;Entecavir Placebo
25 Safety and Immunogenicity Study of Recombinant Thrombin (rThrombin) in Pediatric Participants Completed NCT00859547 Phase 4
26 Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1—Infected Patients Completed NCT01332227 Phase 4 Atazanavir;Ritonavir (heat-stable);Raltegravir;Tenofovir/Emtricitabine
27 A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed Episode Completed NCT00277212 Phase 4 Lamotrigine + Aripiprazole;Lamotrigine + Placebo
28 Study of Reyataz in HIV-infected Patients With Lipodystrophy Syndrome Completed NCT00135356 Phase 4 Atazanavir (ATV) + ritonavir (RTV), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (NRTIs);continuation of current HAART (boosted protease inhibitor [PI] combination + 2 NRTIs)
29 Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy Volunteers Completed NCT01766050 Phase 4 Caffeine;Losartan;Omeprazole;Dextromethorphan;Midazolam
30 Induction-Maintenance With Atazanavir in HIV Naïve Patients (The INDUMA Study) Completed NCT00207142 Phase 4 Atazanavir + 2 NRTIs;Atazanavir + Ritonavir + 2 NRTIs
31 A Randomized Double-Blind Controlled Trial of Creatine in Female Methamphetamine Users Recruiting NCT02192931 Phase 4 Creatine monohydrate
32 Effects of Intranasal Oxytocin on Cigarette Smoking Recruiting NCT02595749 Phase 4 Oxytocin;Placebo
33 Extended Release Naltrexone for Opioid-Dependent Youth Active, not recruiting NCT01843023 Phase 4 Extended Release Naltrexone;Buprenorphine
34 Oxytocin and Cognitive Behavioral Therapy in Drug Dependence Terminated NCT00975416 Phase 4 Intranasal Oxytocin;Placebo
35 Long-Acting Injectable Naltrexone Treatment of Alcohol Dependence in Primary Care vs. in Specialized Chemical Dependence Treatment: A Pilot Trial Terminated NCT00461890 Phase 4 Injectable Naltrexone
36 Anxiety in Recovering Opiate Dependence Terminated NCT00668265 Phase 4 Quetiapine
37 Buprenorphine as a Treatment in Opiate Dependent Pain Patients Terminated NCT00552578 Phase 4 buprenorphine/naloxone;buprenorphine/naloxone
38 Comparison of Buprenorphine/Naloxone With Naltrexone in Opioid Dependent Adolescents Withdrawn NCT01015066 Phase 4 Buprenorphine/naloxone;Naltrexone
39 Comparing Acute and Continuous Drug Abuse Treatment: A Randomized Clinical Trial Unknown status NCT01003496 Phase 3
40 Tobacco Intervention in Buprenorphine Treatment Unknown status NCT01350011 Phase 3
41 A Pilot Study to Evaluate the Effect of Forsteo (Teriparatide, 1-34-rh-PTH) in Anorexia Nervosa Patients With Low Bone Mineral Density and Increased Bone Fagility (FAN-Trial) Unknown status NCT01801397 Phase 3 osteoanabolic therapy
42 Combined Therapy of Methadone and Dextromethrophan Unknown status NCT01189097 Phase 3 Dextromethorphan;Dextromethorphan
43 Job-Seekers Training for Patients With Drug Dependence - 1 Completed NCT00102362 Phase 3
44 Cocaine/Crack and Reduction of Compulsion With Biperiden Completed NCT01251393 Phase 3 Biperiden;Placebo
45 Making Alcoholics Anonymous Easier Completed NCT01382316 Phase 3
46 Prometa Pharmacotherapy for Methamphetamine Dependence Completed NCT00260481 Phase 2, Phase 3 Prometa;Placebo
47 Recovery Housing For Drug Dependent Pregnant Women Completed NCT00497302 Phase 2, Phase 3
48 Treating the Partners of Drug Using Pregnant Women: Stage II Completed NCT00496990 Phase 2, Phase 3
49 Addiction Health Evaluation And Disease Management (AHEAD) Study Completed NCT00278447 Phase 3
50 Assessing Screening Plus Brief Intervention's Resulting Efficacy (ASPIRE) to Stop Drug Use Completed NCT00876941 Phase 3

Search NIH Clinical Center for Drug Dependence

Genetic Tests for Drug Dependence

Anatomical Context for Drug Dependence

MalaCards organs/tissues related to Drug Dependence:

41
Brain, Breast, Myeloid, Testes, Lung, Prostate, Kidney

Publications for Drug Dependence

Articles related to Drug Dependence:

(show top 50) (show all 594)
# Title Authors Year
1
A Case of Drug Dependence Syndrome to Baclofen Following High-Dose Therapy. ( 29621092 )
2018
2
The Role of Aging, Drug Dependence, and Hepatitis C Comorbidity in Alcoholism Cortical Compromise. ( 29541774 )
2018
3
Patients treated with oxaliplatin are at risk for thrombocytopenia caused by multiple drug-dependent antibodies. ( 29439950 )
2018
4
Predictors of Inpatient Treatment Completion among Females with Opioid Use Disorder: Findings from a Tertiary Care Drug Dependence Treatment Centre of India. ( 28852241 )
2017
5
Association of the PLCB1 gene with drug dependence. ( 28860459 )
2017
6
Hospitalizations for Endocarditis and Associated Health Care Costs Among Persons with Diagnosed Drug Dependence - North Carolina, 2010-2015. ( 28594786 )
2017
7
Identifying Life-Threatening Admissions for Drug Dependence or Abuse (ILIADDA): Derivation and Validation of a Model. ( 28290530 )
2017
8
Comparisons of Alcohol and Drug Dependence in Terms of Attachments and Clinical Issues. ( 28742416 )
2017
9
Patients with Infectious Endocarditis and Drug Dependence Have Worse Clinical Outcomes after Valvular Surgery. ( 28099093 )
2017
10
Association between severity of illicit drug dependence and quality of life in a psychosocial care center in BRAZIL: cross-sectional study. ( 29149893 )
2017
11
Prescribed drug dependence services for long-term BZD use: treating the problem while ignoring its causes. ( 29074682 )
2017
12
Pharmacovigilance in drugs used in the treatment of drug dependence. ( 29085108 )
2017
13
The relationship between fear extinction and resilience to drug-dependence in rats. ( 28322983 )
2017
14
Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian tumor cells. ( 28038466 )
2017
15
Acute pain management in patients with drug dependence syndrome. ( 29392226 )
2017
16
Does the choice of thrombotic prophylactic drug depend on the known risk factors of patients with multiple myeloma in clinical practice? ( 27208979 )
2016
17
Effects of Ayahuasca and its Alkaloids on Drug Dependence: A Systematic Literature Review of Quantitative Studies in Animals and Humans. ( 27230395 )
2016
18
Evidence of Shared Genome-Wide Additive Genetic Effects on Interpersonal Trauma Exposure and Generalized Vulnerability to Drug Dependence in a Population of Substance Users. ( 27214850 )
2016
19
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency. ( 26657151 )
2016
20
Profile of female patients seeking in-patient treatment for prescription opioid abuse from a tertiary care drug dependence treatment centre from India. ( 26997020 )
2016
21
Barriers to community-based drug dependence treatment: implications for police roles, collaborations and performance indicators. ( 27435714 )
2016
22
Abstinence From Drug Dependence After Bilateral Globus Pallidus Hypoxic-Ischemic Injury. ( 27311800 )
2016
23
Three Types of Adverse Childhood Experiences, and Alcohol and Drug Dependence Among Adults: An Investigation Using Population-Based Data. ( 27326749 )
2016
24
Estimated probability of becoming a case of drug dependence in relation to duration of drug-taking experience: a functional analysis approach. ( 27356948 )
2016
25
Synthetic cannabinoids to avoid urine drug screens: Implications for contingency management and other treatments for drug dependence. ( 27424166 )
2016
26
Barriers in Access to the Treatment for People with Gambling Disorders. Are They Different from Those Experienced by People with Alcohol and/or Drug Dependence? ( 27832520 )
2016
27
Ibogaine for treating drug dependence. What is a safe dose? ( 27426011 )
2016
28
Illicit Drug Dependence ( 27227249 )
2016
29
A Retrospective Chart Review of Treatment Completers Versus Noncompleters Among In-patients at a Tertiary Care Drug Dependence Treatment Centre in India. ( 27570339 )
2016
30
Drug Dependence Treatment Awareness among Japanese Female Stimulant Drug Offenders. ( 27845738 )
2016
31
Mortality and illicit drug dependence among hemodialysis patients in the United States: a retrospective cohort analysis. ( 27278934 )
2016
32
Stressful Events and Other Predictors of Remission from Drug Dependence in the United States: Longitudinal Results from a National Survey. ( 27776676 )
2016
33
Tryptophan for the sleeping disorder and mental symptom of new-type drug dependence: A randomized, double-blind, placebo-controlled trial. ( 27428201 )
2016
34
Severe Psychosis, Drug Dependence, and Hepatitis C Related to Slamming Mephedrone. ( 27247820 )
2016
35
Evidence for Association Between Low Frequency Variants in CHRNA6/CHRNB3 and Antisocial Drug Dependence. ( 27085880 )
2016
36
Distinct transcriptome profiles differentiate nonsteroidal anti-inflammatory drug-dependent from nonsteroidal anti-inflammatory drug-independent food-induced anaphylaxis. ( 26194548 )
2016
37
Patterns of drug dependence in a Queensland (Australia) sample of Indigenous and non-Indigenous people who inject drugs. ( 27241554 )
2016
38
Psychosocial functioning, quality of life and clinical correlates of comorbid alcohol and drug dependence syndromes in people with schizophrenia across Europe. ( 27046394 )
2016
39
The Two Faces of Social Interaction Reward in Animal Models of Drug Dependence. ( 26088685 )
2015
40
[Role of intracellular Ca2+ dynamics in the development of drug dependence--Participation of Inositol 1,4,5-trisphosphate receptors]. ( 26255430 )
2015
41
Testing for drugs in exhaled breath collected with ExaBreathAr in a drug dependence population: comparison with data obtained in urine after LC-MS/MS analyses. ( 26222873 )
2015
42
Patterns of Methylphenidate Use and Assessment of Its Abuse among the General Population and Individuals with Drug Dependence. ( 26491869 )
2015
43
Stress and Drug Dependence Differentially Modulate Norepinephrine Signaling in Animals with Varied HPA Axis Function. ( 25601230 )
2015
44
Association between DRD2/ANKK1 TaqIA polymorphism and common illicit drug dependence: evidence from a meta-analysis. ( 25500252 )
2015
45
WHO Expert Committee on Drug Dependence. Thirty-sixth report. ( 26062388 )
2015
46
Examining the role of common genetic variants on alcohol, tobacco, cannabis and illicit drug dependence: genetics of vulnerability to drug dependence. ( 25424661 )
2015
47
Salutogenesis: Contextualising place and space in the policies and politics of recovery from drug dependence (UK). ( 26616849 )
2015
48
Association between experience of child abuse and severity of drug addiction measured by the Addiction Severity Index among Japanese drug-dependent patients. ( 25741639 )
2015
49
Negative mood reverses devaluation of goal-directed drug-seeking favouring an incentive learning account of drug dependence. ( 26041336 )
2015
50
Facilitating a transition from compulsory detention of people who use drugs towards voluntary community-based drug dependence treatment and support services in Asia. ( 26470779 )
2015

Variations for Drug Dependence

Expression for Drug Dependence

Search GEO for disease gene expression data for Drug Dependence.

Pathways for Drug Dependence

Pathways related to Drug Dependence according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.77 ACKR1 CHRM2 CNR1 CRH DRD2 DRD3
2
Show member pathways
12.77 ACKR1 CHRM2 CHRNA6 CHRNB3 CNR1 CRH
3
Show member pathways
11.7 BDNF DRD2 PDYN
4
Show member pathways
11.67 CHRM2 DRD2 DRD3
6 11.64 OPRD1 OPRM1 POMC
7
Show member pathways
11.55 CHRNA6 DRD2 DRD3
8 11.47 ACKR1 CHRM2 CNR1 DRD3
9 10.82 DRD2 DRD3
10 10.17 CRH POMC

GO Terms for Drug Dependence

Cellular components related to Drug Dependence according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 neuronal cell body GO:0043025 9.85 CHRM2 CRH OPRK1 PDYN PENK
2 postsynaptic membrane GO:0045211 9.8 CHRM2 CHRNA6 CHRNB3 OPRD1
3 axon GO:0030424 9.8 BDNF CNR1 DRD2 OPRM1 PENK
4 dendrite GO:0030425 9.8 BDNF CHRM2 DRD2 OPRK1 OPRM1 PDYN
5 membrane raft GO:0045121 9.78 CNR1 OPRD1 OPRM1 SLC6A4
6 perikaryon GO:0043204 9.72 CRH DRD2 OPRK1 OPRM1 PENK
7 neuron projection GO:0043005 9.7 CHRNA6 CHRNB3 OPRD1 OPRK1 OPRL1 OPRM1
8 integral component of plasma membrane GO:0005887 9.7 CHRM2 CHRNA6 CHRNB3 CNR1 DRD2 DRD3
9 acetylcholine-gated channel complex GO:0005892 9.51 CHRNA6 CHRNB3
10 symmetric synapse GO:0032280 9.43 CHRM2 PENK
11 axon terminus GO:0043679 9.1 CHRM2 DRD2 OPRD1 OPRK1 PDYN PENK
12 integral component of membrane GO:0016021 10.3 ACKR1 CHRM2 CHRNA6 CHRNB3 CNR1 DRD2
13 plasma membrane GO:0005886 10.21 ACKR1 CHRM2 CHRNA6 CHRNB3 CNR1 DRD2

Biological processes related to Drug Dependence according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.95 CHRM2 CNR1 OPRD1 OPRK1 OPRL1 OPRM1
2 response to ethanol GO:0045471 9.95 CNR1 CRH DRD2 DRD3 OPRK1 OPRM1
3 locomotory behavior GO:0007626 9.93 DRD2 DRD3 OPRK1 OPRM1 PENK
4 response to nicotine GO:0035094 9.91 CHRNA6 CHRNB3 CNR1 DRD2 PENK
5 sensory perception of pain GO:0019233 9.91 CNR1 OPRD1 OPRK1 OPRL1 OPRM1 PENK
6 neuropeptide signaling pathway GO:0007218 9.91 OPRD1 OPRK1 OPRL1 OPRM1 PDYN PENK
7 response to toxic substance GO:0009636 9.89 DRD2 PENK SLC6A4
8 response to estradiol GO:0032355 9.88 OPRL1 PENK SLC6A4
9 excitatory postsynaptic potential GO:0060079 9.88 CHRNA6 CHRNB3 DRD2 OPRM1
10 adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway GO:0007193 9.87 OPRD1 OPRK1 OPRL1 OPRM1
11 negative regulation of blood pressure GO:0045776 9.86 CNR1 DRD2 DRD3 OPRL1
12 memory GO:0007613 9.85 BDNF CNR1 SLC6A4
13 phospholipase C-activating G-protein coupled receptor signaling pathway GO:0007200 9.85 OPRD1 OPRK1 OPRM1
14 adenylate cyclase-modulating G-protein coupled receptor signaling pathway GO:0007188 9.85 CHRM2 CNR1 DRD2
15 regulation of sensory perception of pain GO:0051930 9.85 OPRD1 OPRK1 OPRL1 OPRM1
16 learning or memory GO:0007611 9.84 CNR1 CRH DRD3
17 response to radiation GO:0009314 9.83 OPRK1 OPRM1 PENK
18 eating behavior GO:0042755 9.83 OPRD1 OPRK1 OPRL1 OPRM1
19 chemical synaptic transmission GO:0007268 9.81 CHRNA6 CHRNB3 CRH OPRD1 OPRK1 OPRL1
20 synaptic transmission, cholinergic GO:0007271 9.8 CHRM2 CHRNA6 CHRNB3
21 opioid receptor signaling pathway GO:0038003 9.8 OPRD1 OPRK1 OPRL1 OPRM1
22 behavioral response to cocaine GO:0048148 9.78 DRD2 DRD3 OPRK1
23 regulation of dopamine secretion GO:0014059 9.77 CHRNA6 DRD2 DRD3
24 synaptic transmission, dopaminergic GO:0001963 9.77 CRH DRD2 DRD3
25 estrous cycle GO:0044849 9.75 OPRK1 OPRL1 OPRM1
26 response to cocaine GO:0042220 9.73 CNR1 CRH DRD2 DRD3 OPRK1 OPRM1
27 dopamine receptor signaling pathway GO:0007212 9.72 DRD2 DRD3
28 negative regulation of protein secretion GO:0050709 9.72 DRD2 DRD3
29 regulation of NMDA receptor activity GO:2000310 9.72 CRH OPRM1
30 sensory perception GO:0007600 9.72 OPRK1 OPRL1 OPRM1 PDYN PENK
31 behavioral response to ethanol GO:0048149 9.71 DRD2 OPRM1
32 startle response GO:0001964 9.71 DRD2 PENK
33 dopamine metabolic process GO:0042417 9.71 DRD2 DRD3
34 positive regulation of renal sodium excretion GO:0035815 9.71 DRD2 DRD3
35 negative regulation of voltage-gated calcium channel activity GO:1901386 9.7 DRD2 OPRL1
36 positive regulation of urine volume GO:0035810 9.7 DRD2 OPRL1
37 locomotory exploration behavior GO:0035641 9.7 CRH PENK
38 regulation of synaptic transmission, GABAergic GO:0032228 9.69 CNR1 DRD2
39 prepulse inhibition GO:0060134 9.69 DRD2 DRD3
40 G-protein coupled receptor internalization GO:0002031 9.69 DRD2 DRD3
41 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.68 DRD2 DRD3
42 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.68 DRD3 OPRM1
43 behavior GO:0007610 9.68 OPRK1 OPRL1
44 negative regulation of adenylate cyclase-activating G-protein coupled receptor signaling pathway GO:0106072 9.66 OPRL1 OPRM1
45 positive regulation of behavioral fear response GO:2000987 9.66 CRH PENK
46 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.65 DRD2 DRD3
47 acid secretion GO:0046717 9.65 DRD2 DRD3
48 negative regulation of dopamine secretion GO:0033602 9.64 CNR1 DRD2
49 negative regulation of luteinizing hormone secretion GO:0033685 9.64 CRH OPRK1
50 negative regulation of dopamine receptor signaling pathway GO:0060160 9.63 DRD2 DRD3

Molecular functions related to Drug Dependence according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor activity GO:0004930 9.81 ACKR1 CHRM2 CNR1 DRD2 DRD3 OPRD1
2 obsolete signal transducer activity GO:0004871 9.8 CNR1 DRD2 DRD3 OPRD1 OPRL1 OPRM1
3 peptide binding GO:0042277 9.71 OPRD1 OPRK1 OPRL1 OPRM1
4 drug binding GO:0008144 9.67 CHRM2 CNR1 DRD2 DRD3
5 neuropeptide hormone activity GO:0005184 9.56 CRH PDYN PENK POMC
6 acetylcholine binding GO:0042166 9.55 CHRNA6 CHRNB3
7 acetylcholine-gated cation-selective channel activity GO:0022848 9.54 CHRNA6 CHRNB3
8 acetylcholine receptor activity GO:0015464 9.52 CHRNA6 CHRNB3
9 dopamine binding GO:0035240 9.51 DRD2 DRD3
10 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.49 DRD2 DRD3
11 dopamine neurotransmitter receptor activity GO:0004952 9.48 DRD2 DRD3
12 opioid peptide activity GO:0001515 9.46 PDYN PENK
13 opioid receptor binding GO:0031628 9.43 PDYN PENK
14 neuropeptide binding GO:0042923 9.26 OPRD1 OPRK1 OPRL1 OPRM1
15 opioid receptor activity GO:0004985 8.92 OPRD1 OPRK1 OPRL1 OPRM1

Sources for Drug Dependence

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....